Approximately 1 in 3,000 people worldwide have neurofibromatosis type 1 (NF1), a common genetic disorder affecting the nervous system. Significantly, 60% of NF1 patients experience chronic pain that may begin long before visible tumors develop along nerve pathways.
Recent research from Cincinnati Children’s Hospital identifies Schwann cell dysfunction as the underlying culprit. These support cells, which normally protect and nourish nerve tissue, produce excess glial cell line-derived neurotrophic factor (GDNF) in NF1 patients—levels reaching 285% above normal baselines. This elevated GDNF drives abnormal pain signaling independently of physical tumor compression.
The study utilized murine models to demonstrate how dysregulated GDNF enhances pain sensitivity. These findings provide critical insight into why pain management in NF1 patients requires approaches targeting cellular mechanisms rather than relying exclusively on tumor-focused interventions.
Read the full article on GMJ Newsroom.
Was this article helpful?
